Analysts at StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Get Free Report) in a research note issued to investors on Thursday. The firm set a “sell” rating on the stock. Several other brokerages have also issued reports on OCX. Stephens reiterated an “equal weight” rating and issued a $4.00 price target on shares […]